Absence of SHIV infection in gut and lymph node tissues in rhesus monkeys after repeated rectal challenges following HIV-1 DNA/MVA immunizations

Vaccine

Volumn 25, Issue 35, 2007, Pages 6474-6481

  Aidoo, Michael ^a   Otten, Ronald A ^a   Rodriguez, Vanessa ^b   Sariol, Carlos A ^b   Martinez, Melween ^b   Kraiselburd, Edmundo ^b   Robinson, Harriet ^c   Folks, Thomas ^a   Butera, Salvatore ^a   Ellenberger, Dennis ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b UNIVERSITY OF PUERTO RICO   (Puerto Rico)

^c EMORY UNIVERSITY   (United States)

Author keywords

DNA MVA vaccine; GALT; Sequestered virus

Indexed keywords

DNA VACCINE; GAG PROTEIN; MVA VACCINE; POL PROTEIN; UNCLASSIFIED DRUG; VIRUS DNA; VIRUS VACCINE;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPSY; CELL ACTIVATION; COCULTURE; CONTROLLED STUDY; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNIZATION; IN VITRO STUDY; INTESTINE INFECTION; LYMPH NODE; LYMPH NODE INFECTION; MACACA; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PHYSIOLOGY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RECTUM; RHESUS MONKEY; SCHISTOSOMA MANSONI; SENSITIVITY ANALYSIS; SIMIAN IMMUNODEFICIENCY VIRUS; SPLEEN; T LYMPHOCYTE; TESTIS; TREMATODIASIS; VIRUS CULTURE;

AIDS VACCINES; ANIMALS; COCULTURE TECHNIQUES; DIGESTIVE SYSTEM; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; FUSION PROTEINS, GAG-POL; HIV CORE PROTEIN P24; HIV-1; IMMUNITY, NATURAL; LYMPH NODES; LYMPHOCYTES; LYMPHOID TISSUE; MACACA MULATTA; MONOCYTES; RECTUM; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; VACCINES, DNA;

EID: 34547578472     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.06.014     Document Type: Article

References (47)

1. Badri M., Maartens G., Mandalia S., Bekker L.G., Penrod J.R., Platt R.W., et al. Cost-effectiveness of highly active antiretroviral therapy in South Africa. PLoS Med 3 1 (2006) e4
2. Weiser S., Wolfe W., Bangsberg D., Thior I., Gilbert P., Makhema J., et al. Barriers to antiretroviral adherence for patients living with HIV infection and AIDS in Botswana. J Acquir Immune Defic Syndr 34 3 (2003) 281-288
3. Jaffar S., Govender T., Garrib A., Welz T., Grosskurth H., Smith P.G., et al. Antiretroviral treatment in resource-poor settings: public health research priorities. Trop Med Int Health 10 4 (2005) 295-299
4. Bautista-Arredondo S., Mane A., and Bertozzi S.M. Economic impact of antiretroviral therapy prescription decisions in the context of rapid scaling-up of access to treatment: lessons from Mexico. AIDS 20 1 (2006) 101-109
5. Svicher V., Sing T., Santoro M.M., Forbici F., Rodriguez-Barrios F., Bertoli A., et al. Involvement of novel human immunodeficiency virus type 1 reverse transcriptase mutations in the regulation of resistance to nucleoside inhibitors. J Virol 80 14 (2006) 7186-7198
6. Johnson J.A., Li J.F., Morris L., Martinson N., Gray G., McIntyre J., et al. Emergence of drug-resistant HIV-1 after intrapartum administration of single-dose nevirapine is substantially underestimated. J Infect Dis 192 1 (2005) 16-23
7. Ono S., Kurotaki T., Nakasone T., Honda M., Boon-Long J., Sawanpanyalert P., et al. Cost-effectiveness analysis of antiretroviral drug treatment and HIV-1 vaccination in Thailand. Jpn J Infect Dis 59 3 (2006) 168-173
8. Brander C., Frahm N., and Walker B.D. The challenges of host and viral diversity in HIV vaccine design. Curr Opin Immunol 18 4 (2006) 430-437
9. McMichael A.J. HIV vaccines. Annu Rev Immunol 24 (2006) 227-255
10. Jin X., Bauer D.E., Tuttleton S.E., Lewin S., Gettie A., Blanchard J., et al. Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques. J Exp Med 189 6 (1999) 991-998
11. Schmitz J.E., Kuroda M.J., Santra S., Sasseville V.G., Simon M.A., Lifton M.A., et al. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 283 5403 (1999) 857-860
12. Koup R.A., Safrit J.T., Cao Y., Andrews C.A., McLeod G., Borkowsky W., et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 68 7 (1994) 4650-4655
13. Borrow P., Lewicki H., Hahn B.H., Shaw G.M., and Oldstone M.B. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 68 9 (1994) 6103-6110
14. Ogg G.S., Jin X., Bonhoeffer S., Dunbar P.R., Nowak M.A., Monard S., et al. Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science 279 5359 (1998) 2103-2106
15. Feeney M.E., Tang Y., Roosevelt K.A., Leslie A.J., McIntosh K., Karthas N., et al. Immune escape precedes breakthrough human immunodeficiency virus type 1 viremia and broadening of the cytotoxic T-lymphocyte response in an HLA-B27-positive long-term-nonprogressing child. J Virol 78 16 (2004) 8927-8930
16. Oxenius A., Price D.A., Trkola A., Edwards C., Gostick E., Zhang H.T., et al. Loss of viral control in early HIV-1 infection is temporally associated with sequential escape from CD8+ T cell responses and decrease in HIV-1-specific CD4+ and CD8+ T cell frequencies. J Infect Dis 190 4 (2004) 713-721
17. Barouch D.H., Kunstman J., Kuroda M.J., Schmitz J.E., Santra S., Peyerl F.W., et al. Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes. Nature 415 6869 (2002) 335-339
18. Mothe B.R., Weinfurter J., Wang C., Rehrauer W., Wilson N., Allen T.M., et al. Expression of the major histocompatibility complex class I molecule Mamu-A*01 is associated with control of simian immunodeficiency virus SIVmac239 replication. J Virol 77 4 (2003) 2736-2740
19. Carrington M., Nelson G.W., Martin M.P., Kissner T., Vlahov D., Goedert J.J., et al. HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage. Science 283 5408 (1999) 1748-1752
20. Amara R.R., Villinger F., Altman J.D., Lydy S.L., O'Neil S.P., Staprans S.I., et al. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 292 5514 (2001) 69-74
21. Buge S.L., Ma H.L., Amara R.R., Wyatt L.S., Earl P.L., Villinger F., et al. Gp120-alum boosting of a Gag-Pol-Env DNA/MVA AIDS vaccine: poorer control of a pathogenic viral challenge. AIDS Res Hum Retroviruses 19 10 (2003) 891-900
22. Ellenberger D., Otten R.A., Li B., Aidoo M., Rodriguez I.V., Sariol C.A., et al. HIV-1 DNA/MVA vaccination reduces the per exposure probability of infection during repeated mucosal SHIV challenges. Virology 325 (2006) 216-225
23. Veazey R.S., DeMaria M., Chalifoux L.V., Shvetz D.E., Pauley D.R., Knight H.L., et al. Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection. Science 280 5362 (1998) 427-431
24. Mehandru S., Poles M.A., Tenner-Racz K., Horowitz A., Hurley A., Hogan C., et al. Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract. J Exp Med 200 6 (2004) 761-770
25. Brenchley J.M., Schacker T.W., Ruff L.E., Price D.A., Taylor J.H., Beilman G.J., et al. CD4+ T cell depletion during all stages of HIV disease occurs predominantly in the gastrointestinal tract. J Exp Med 200 6 (2004) 749-759
26. Mattapallil J.J., Douek D.C., Hill B., Nishimura Y., Martin M., and Roederer M. Massive infection and loss of memory CD4+ T cells in multiple tissues during acute SIV infection. Nature 434 7037 (2005) 1093-1097
27. Li Q., Duan L., Estes J.D., Ma Z.M., Rourke T., Wang Y., et al. Peak SIV replication in resting memory CD4+ T cells depletes gut lamina propria CD4+ T cells. Nature 434 7037 (2005) 1148-1152
28. Shacklett B.L., Yang O., Hausner M.A., Elliott J., Hultin L., Price C., et al. Optimization of methods to assess human mucosal T-cell responses to HIV infection. J Immunol Meth 279 1/2 (2003) 17-31
29. Gao F., Yue L., Robertson D.L., Hill S.C., Hui H., Biggar R.J., et al. Genetic diversity of human immunodeficiency virus type 2: evidence for distinct sequence subtypes with differences in virus biology. J Virol 68 11 (1994) 7433-7447
30. Bertley F.M., Kozlowski P.A., Wang S.W., Chappelle J., Patel J., Sonuyi O., et al. Control of simian/human immunodeficiency virus viremia and disease progression after IL-2-augmented DNA-modified vaccinia virus Ankara nasal vaccination in nonhuman primates. J Immunol 172 6 (2004) 3745-3757
31. Wilson N.A., Reed J., Napoe G.S., Piaskowski S., Szymanski A., Furlott J., et al. Vaccine-induced cellular immune responses reduce plasma viral concentrations after repeated low-dose challenge with pathogenic simian immunodeficiency virus SIVmac239. J Virol 80 12 (2006) 5875-5885
32. Zink M.C., Suryanarayana K., Mankowski J.L., Shen A., Piatak M.J., Spelman J.P., et al. High viral load in the cerebrospinal fluid and brain correlates with severity of simian immunodeficiency virus encephalitis. J Virol 73 12 (1999) 10480-10488
33. Miyake A., Ibuki K., Enose Y., Suzuki H., Horiuchi R., Motohara M., et al. Rapid dissemination of a pathogenic simian/human immunodeficiency virus to systemic organs and active replication in lymphoid tissues following intrarectal infection. J Gen Virol 87 Pt 5 (2006) 1311-1320
34. Hockett R.D., Kilby J.M., Derdeyn C.A., Saag M.S., Sillers M., Squires K., et al. Constant mean viral copy number per infected cell in tissues regardless of high, low, or undetectable plasma HIV RNA. J Exp Med 189 10 (1999) 1545-1554
35. Sankaran S., Guadalupe M., Reay E., George M.D., Flamm J., Prindiville T., et al. Gut mucosal T cell responses and gene expression correlate with protection against disease in long-term HIV-1-infected nonprogressors. Proc Natl Acad Sci USA 102 28 (2005) 9860-9865
36. Ma Z.M., Abel K., Rourke T., Wang Y., and Miller C.J. A period of transient viremia and occult infection precedes persistent viremia and antiviral immune responses during multiple low-dose intravaginal simian immunodeficiency virus inoculations. J Virol 78 24 (2004) 14048-14052
37. Mattapallil J.J., Douek D.C., Buckler-White A., Montefiori D., Letvin N.L., Nabel G.J., et al. Vaccination preserves CD4 memory T cells during acute simian immunodeficiency virus challenge. J Exp Med 203 6 (2006) 1533-1541
38. Pal R., Venzon D., Santra S., Kalyanaraman V.S., Montefiori D.C., Hocker L., et al. Systemic immunization with an ALVAC-HIV-1/protein boost vaccine strategy protects rhesus macaques from CD4+ T-cell loss and reduces both systemic and mucosal simian-human immunodeficiency virus SHIVKU2 RNA levels. J Virol 80 8 (2006) 3732-3742
39. Letvin N.L., Mascola J.R., Sun Y., Gorgone D.A., Buzby A.P., Xu L., et al. Preserved CD4+ central memory T cells and survival in vaccinated SIV-challenged monkeys. Science 312 5779 (2006) 1530-1533
40. Kozyrev I.L., Ibuki K., Shimada T., Kuwata T., Takemura T., Hayami M., et al. Characterization of less pathogenic infectious molecular clones derived from acute-pathogenic SHIV-89.6p stock virus. Virology 282 1 (2001) 6-13
41. Dioszeghy V., lhassan-Chahour K., Delache B., Dereuddre-Bosquet N., Aubenque C., Gras G., et al. Changes in soluble factor-mediated CD8+ cell-derived antiviral activity in cynomolgus macaques infected with simian immunodeficiency virus SIVmac251: relationship to biological markers of progression. J Virol 80 1 (2006) 236-245
42. Kannagi M., Chalifoux L.V., Lord C.I., and Letvin N.L. Suppression of simian immunodeficiency virus replication in vitro by CD8+ lymphocytes. J Immunol 140 7 (1988) 2237-2242
43. Ellenberger D., Li B., Smith J., Yi H., Folks T., Robinson H., et al. Optimization of a multi-gene HIV-1 recombinant subtype CRF02_AG DNA vaccine for expression of multiple immunogenic forms. Virology 319 1 (2004) 118-130
44. Teleshova N., Kenney J., Jones J., Marshall J., Van Nest G., Dufour J., et al. CpG-C immunostimulatory oligodeoxyribonucleotide activation of plasmacytoid dendritic cells in rhesus macaques to augment the activation of IFN-gamma-secreting simian immunodeficiency virus-specific T cells. J Immunol 173 3 (2004) 1647-1657
45. Fonteneau J.F., Larsson M., Beignon A.S., McKenna K., Dasilva I., Amara A., et al. Human immunodeficiency virus type 1 activates plasmacytoid dendritic cells and concomitantly induces the bystander maturation of myeloid dendritic cells. J Virol 78 10 (2004) 5223-5232
46. Wick W.D., Gilbert P.B., and Self S.G. On modeling HIV and T cells in vivo: assessing causal estimators in vaccine trials. PLoS Comput Biol 2 6 (2006) e64
47. Rowland-Jones S.L., and McMichael A. Immune responses in HIV-exposed seronegatives: have they repelled the virus?. Curr Opin Immunol 7 4 (1995) 448-455